{
  "docId": "019de075-dd1e-7468-9323-d12fde1b7732",
  "docSlug": "a9cc0c508d45d8985f57408ace49b969",
  "documentTitle": "RayzeBio | IPO Presentation Deck | 41 slides",
  "authorId": "rayzebio",
  "authorName": "RayzeBio",
  "documentKindSlug": "pitchdeck",
  "documentKindLabel": "Pitch deck",
  "sourceTypeSlug": "investment_bank",
  "sourceTypeLabel": "Investment bank",
  "presentationDate": "2023-09-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7761332,
  "pageNumber": 12,
  "pageCount": 41,
  "prevPage": 11,
  "nextPage": 13,
  "slideType": "problem_statement",
  "function": "frame_problem",
  "density": "balanced",
  "nDataPoints": 1,
  "notes": "The slide uses a process flow diagram to show the standard of care progression for two types of NETs.",
  "elementsJson": null,
  "metadataConfidence": 0.95,
  "imagePath": null,
  "slideHref": "/slides/019de075-dd1e-7468-9323-d12fde1b7732/12",
  "deckHref": "/decks/019de075-dd1e-7468-9323-d12fde1b7732",
  "deckJsonHref": "/decks/019de075-dd1e-7468-9323-d12fde1b7732.json",
  "deckAnchorHref": "/decks/019de075-dd1e-7468-9323-d12fde1b7732#slide-12",
  "components": [
    {
      "bbox": {
        "h": 0.6,
        "w": 0.45,
        "x": 0.5,
        "y": 0.2
      },
      "kind": "diagram",
      "text": "Management of Advanced/Metastatic, Well-Differentiated SSTR+ NETs. GI-NET and P-NET treatment pathways showing progression from somatostatin analogs to chemotherapy/targeted therapy to 177Lu-DOTATATE.",
      "attrs": null,
      "subkind": "process",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "56089057-03eb-4888-9790-8b918858a2cb",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.4,
        "w": 0.4,
        "x": 0.03,
        "y": 0.2
      },
      "kind": "paragraph",
      "text": "Neuroendocrine tumors of the GI tract (GI-NET) and pancreas (P-NET) have limited treatment options. Somatostatin receptor 2 (SSTR2) is expressed in 80-90% of GEP-NETs. Limited FDA approved treatments and invariable disease progression. 177Lu-DOTATATE (Lutathera) approved in 2018 was a major advance for NET patients.",
      "attrs": null,
      "subkind": "paragraph",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "fdbd6f8b-7d5a-4953-8276-c60455b3f83d",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.05,
        "w": 0.6,
        "x": 0.03,
        "y": 0.05
      },
      "kind": "title",
      "text": "Lead Clinical Indication – Refractory Neuroendocrine Tumors (NETs)",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "a5ef4420-63c5-412f-aa75-b1341a208501",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [],
  "frameworks": [
    {
      "name": "process",
      "slug": null,
      "matchId": "a09cd407-62e9-475a-bb66-ad3b9aa09e53",
      "evidence": "The slide uses a flow chart to depict the clinical treatment pathway for NET patients.",
      "confidence": 0.8
    }
  ],
  "arcBeats": [
    {
      "to": 12,
      "from": 9,
      "beatId": "c50d4ad9-887f-4c32-8d82-c72b06c2e782",
      "arcName": "The Sequoia Pitch",
      "arcSlug": "sequoia-pitch",
      "beatName": "Problem",
      "beatSlug": "sequoia-pitch-problem",
      "evidence": "The document presents the problem statement, highlighting the limitations of current cancer treatments and the unmet need in NETs.",
      "position": 0,
      "confidence": 0.8,
      "parentBeatName": "Complication",
      "parentBeatSlug": "complication"
    }
  ],
  "loops": [
    {
      "to": 14,
      "from": 12,
      "name": "Cost Of Inaction",
      "slug": "27-cost-of-inaction",
      "bestFor": "Urgent budget requests, compliance, risk mitigation",
      "matchId": "53cf3362-2492-4fd7-a1a1-affed636c3a5",
      "evidence": "The document highlights the unmet need in NETs and the potential market opportunity.",
      "position": 0,
      "objective": "What is the cost of inaction in addressing the unmet need in NETs?",
      "structure": "The Status Quo -> The Hidden Costs Accumulating -> The Future State of Inaction -> The Tipping Point",
      "confidence": 0.7,
      "description": "Quantify what happens if the audience does nothing"
    }
  ],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}